Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DHX29_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DHX29_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DHX29_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DHX29_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DHX29_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004225529 | Skin | cSCC | ribosome assembly | 44/4864 | 61/18723 | 5.84e-14 | 3.81e-12 | 44 |
GO:000173115 | Skin | cSCC | formation of translation preinitiation complex | 10/4864 | 11/18723 | 1.17e-05 | 1.50e-04 | 10 |
GO:00459484 | Skin | cSCC | positive regulation of translational initiation | 18/4864 | 30/18723 | 8.53e-05 | 8.08e-04 | 18 |
GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
GO:0002181113 | Thyroid | PTC | cytoplasmic translation | 121/5968 | 148/18723 | 4.32e-36 | 4.54e-33 | 121 |
GO:0006413112 | Thyroid | PTC | translational initiation | 84/5968 | 118/18723 | 1.89e-18 | 2.09e-16 | 84 |
GO:0071826113 | Thyroid | PTC | ribonucleoprotein complex subunit organization | 134/5968 | 227/18723 | 2.34e-17 | 2.24e-15 | 134 |
GO:0006417113 | Thyroid | PTC | regulation of translation | 236/5968 | 468/18723 | 2.70e-17 | 2.52e-15 | 236 |
GO:0022618113 | Thyroid | PTC | ribonucleoprotein complex assembly | 130/5968 | 220/18723 | 6.25e-17 | 5.47e-15 | 130 |
GO:0034250113 | Thyroid | PTC | positive regulation of cellular amide metabolic process | 98/5968 | 162/18723 | 5.26e-14 | 3.04e-12 | 98 |
GO:0045727113 | Thyroid | PTC | positive regulation of translation | 84/5968 | 136/18723 | 6.52e-13 | 3.08e-11 | 84 |
GO:0006446110 | Thyroid | PTC | regulation of translational initiation | 55/5968 | 79/18723 | 6.21e-12 | 2.63e-10 | 55 |
GO:0042255113 | Thyroid | PTC | ribosome assembly | 43/5968 | 61/18723 | 6.72e-10 | 2.04e-08 | 43 |
GO:0002183112 | Thyroid | PTC | cytoplasmic translational initiation | 27/5968 | 34/18723 | 1.57e-08 | 3.69e-07 | 27 |
GO:000173117 | Thyroid | PTC | formation of translation preinitiation complex | 9/5968 | 11/18723 | 9.49e-04 | 5.70e-03 | 9 |
GO:00459485 | Thyroid | PTC | positive regulation of translational initiation | 17/5968 | 30/18723 | 4.31e-03 | 2.04e-02 | 17 |
GO:002261334 | Thyroid | ATC | ribonucleoprotein complex biogenesis | 292/6293 | 463/18723 | 3.05e-39 | 9.63e-36 | 292 |
GO:004225434 | Thyroid | ATC | ribosome biogenesis | 203/6293 | 299/18723 | 3.63e-34 | 4.59e-31 | 203 |
GO:000218135 | Thyroid | ATC | cytoplasmic translation | 121/6293 | 148/18723 | 1.41e-33 | 1.49e-30 | 121 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DHX29 | SNV | Missense_Mutation | novel | c.1207C>G | p.Pro403Ala | p.P403A | Q7Z478 | protein_coding | tolerated(0.41) | benign(0) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
DHX29 | SNV | Missense_Mutation | rs746293690 | c.1795A>G | p.Ser599Gly | p.S599G | Q7Z478 | protein_coding | tolerated(0.06) | probably_damaging(0.964) | TCGA-AN-A0XT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
DHX29 | SNV | Missense_Mutation | | c.3761N>G | p.Ala1254Gly | p.A1254G | Q7Z478 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
DHX29 | SNV | Missense_Mutation | | c.1834N>C | p.Asp612His | p.D612H | Q7Z478 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
DHX29 | SNV | Missense_Mutation | | c.1539N>C | p.Lys513Asn | p.K513N | Q7Z478 | protein_coding | tolerated(0.26) | benign(0.021) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DHX29 | SNV | Missense_Mutation | novel | c.1033N>C | p.Glu345Gln | p.E345Q | Q7Z478 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
DHX29 | deletion | Frame_Shift_Del | novel | c.1065delN | p.Asp356IlefsTer9 | p.D356Ifs*9 | Q7Z478 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
DHX29 | SNV | Missense_Mutation | novel | c.2900A>G | p.Glu967Gly | p.E967G | Q7Z478 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DHX29 | SNV | Missense_Mutation | rs778194125 | c.2494C>T | p.Arg832Cys | p.R832C | Q7Z478 | protein_coding | deleterious(0) | possibly_damaging(0.719) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DHX29 | SNV | Missense_Mutation | | c.532G>A | p.Glu178Lys | p.E178K | Q7Z478 | protein_coding | tolerated(0.89) | benign(0.001) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |